Hanash
Alan Hanash, New York, NY US
Patent application number | Description | Published |
---|---|---|
20140248235 | Methods of Use for IL-22 Promoting Rejuvenation Of Thymic And Bone Marrow Function - The present invention provides methods and compositions for the use of IL-22 to promote thymic growth following thymic insult. In particularly preferred embodiments, the present invention provides methods of using therapeutic IL-22 compositions for treating patients with thymic atrophy and alterations in bone marrow derived white blood cells, including cancer patients undergoing chemotherapy, patients exposed to radiation (i.e. cancer therapy, nuclear disaster, terrorist attack, etc.), patients with HIV infections/AIDS, patients with organ transplantation, aging patients, and the like. In a further embodiment, therapeutic IL-22 compositions are contemplated as a prophylactic to boost immune response when additional T-cell function is needed, i.e. to boost immune response during vaccination. | 09-04-2014 |
Samir Hanash, Mercer Island, WI US
Patent application number | Description | Published |
---|---|---|
20090047689 | AUTOANTIGEN BIOMARKERS FOR EARLY DIAGNOSIS OF LUNG ADENOCARCINOMA - Provided herein are novel panels of biomarkers for the detection and diagnosis of lung adenocarcinoma, and methods and kits for detecting these biomarkers in samples of individuals suspected of having the disease. Also provided are methods of monitoring the progression of lung adenocarcinoma and methods of monitoring the efficacy of a treatment. | 02-19-2009 |
20100055704 | EXPRESSION PROFILE OF THYROID CANCER - The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides gene expression profiles associated with thyroid cancers. Genes identified as cancer markers using the methods of the present invention find use in the diagnosis and characterization of thyroid cancer. In addition, the genes provide targets for cancer drug screens and therapeutic applications. | 03-04-2010 |
20110201517 | AUTOANTIGEN BIOMARKERS FOR EARLY DIAGNOSIS OF LUNG ADENOCARCINOMA - Provided herein are novel panels of biomarkers for the detection and diagnosis of lung adenocarcinoma, and methods and kits for detecting these biomarkers in samples of individuals suspected of having the disease. Also provided are methods of monitoring the progression of lung adenocarcinoma and methods of monitoring the efficacy of a treatment. | 08-18-2011 |
Samir Hanash, Houston, TX US
Patent application number | Description | Published |
---|---|---|
20160060329 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND PROGNOSIS OF LUNG CANCER - The present invention relates to methods and compositions for the detection of lung cancer. More particularly, the present invention provides monoclonal antibodies for the detection of lung cancer. | 03-03-2016 |
Samir M. Hanash, Ann Arbor, MI US
Patent application number | Description | Published |
---|---|---|
20100330587 | Annexin Proteins and Autoantibodies As Serum Markers For Cancer - The present invention relates to screening methods for diagnosis, prognosis, or susceptibility to cancer in a subject by means of detecting the presence of serum autoantibodies to specific annexin protein antigens in sera from subjects. The present invention also provides screening methods for diagnosis and prognosis of cancer in a subject by means of detecting increased expression levels of annexin proteins in biological samples of the subject. The method of the invention can also be used to identify subjects at risk for developing cancer. The method of the invention involves the use of subject derived biological samples to determine the occurrence and level of expression of annexin proteins or expression of annexin derived peptides or antigens, and/or the occurrence and level of circulating autoantibodies to specific annexin protein antigens. The present invention further provides for kits for carrying out the above described screening methods. Such kits can be used to screen subjects for increased levels of annexin proteins, or for the detection of autoantibodies to annexin proteins, as a diagnostic, predictive or prognostic indicator of cancer. | 12-30-2010 |
20130177927 | Protein markers for esophageal cancer - Computerized analysis of 2-D gels, both carrier ampholyte (CA) and immobilized pH gradient (IPG) based, of the proteins in tissue from esophageal tumors, reveals proteins which are different in tumor and control tissue. | 07-11-2013 |
Samir M. Hanash, Mercer Island, WA US
Patent application number | Description | Published |
---|---|---|
20100092476 | PANCREATIC CANCER BIOMARKERS - The present invention provides a method of diagnosing, prognosing or screening for pancreatic cancer in a subject. The method may be carried out on a sample such as a blood or tissue sample collected from the subject. The is carried out by (a) detecting one or more markers in a biological sample of said subject, said markers selected from the markers set forth in Table 1 (e.g. one or more markers selected from the group set forth in Table 2, and/or the group consisting of ALCAM, TIMP-1, ICAM1, LCN2, REG1A, REG3, IGFBP4, TNFRSF1A and WFDC2); and (b) determining an altered level of said marker(s), said altered level indicating said subject may be afflicted with or at risk of developing pancreatic cancer. Kits useful for carrying out the methods are also described. | 04-15-2010 |
20120100558 | LUNG CANCER DIAGNOSIS - Diagnosis of lung cancer in a subject before onset of symptoms is described herein (i.e., in a pre-diagnostic subject), by screening a biological fluid from the subject for the presence therein of autoantibodies that are specific for one or more pre-diagnostic lung cancer indicator proteins, including LAMR1, and optionally additionally or alternatively including annexin I and/or 14-3-3-theta and/or other pre-diagnostic lung cancer indicator proteins as presently disclosed, as the defined antigens. Related methods, including for monitoring immune reactivity against lung cancer indicator proteins in a lung cancer patient, typing lung cancer subjects or characterizing lung tumors, and application of the described proteomics approach for the identification of additional pre-diagnostic lung cancer indicator proteins, are also contemplated. | 04-26-2012 |
20130115232 | Methods for detecting graft-versus-host disease - The disclosure relates to the development of methods for detecting or predicting graft-versus-host disease (GVHD) and for detecting or predicting response to treatment for GVHD. More particularly, the disclosure provides new biomarkers and combinations of biomarkers for detecting or predicting gastrointestinal GI GVHD and for predicting and analyzing response to treatment for acute GVHD. | 05-09-2013 |